{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T16:39:21Z","timestamp":1776962361729,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,6,29]],"date-time":"2018-06-29T00:00:00Z","timestamp":1530230400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1038\/s41397-018-0031-7","type":"journal-article","created":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T17:01:56Z","timestamp":1530118916000},"page":"740-748","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder"],"prefix":"10.1038","volume":"18","author":[{"given":"Yaowaluck","family":"Hongkaew","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadeep","family":"Medhasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekawat","family":"Pasomsub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nattawat","family":"Ngamsamut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apichaya","family":"Puangpetch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natchaya","family":"Vanwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monpat","family":"Chamnanphon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penkhae","family":"Limsila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuthamanee","family":"Suthisisang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bob","family":"Wilffert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chonlaphat","family":"Sukasem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,29]]},"reference":[{"key":"31_CR1","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.biopsych.2006.09.021","volume":"61","author":"TC Bethea","year":"2007","unstructured":"Bethea TC, Sikich L. Early pharmacological treatment of autism: a rationale for developmental treatment. Biol Psychiatry. 2007;61:521\u201337.","journal-title":"Biol Psychiatry"},{"key":"31_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1089\/cap.2007.0041","volume":"18","author":"MS Parikh","year":"2008","unstructured":"Parikh MS, Kolevzon A, Hollander E. Psychopharmacology of aggression in children and adolescents with autism: a critical review of efficacy and tolerability. J Child Adolesc Psychopharmacol. 2008;18:157\u201378.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"31_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/cap.2007.0098","volume":"18","author":"M Haas","year":"2008","unstructured":"Haas M, Karcher K, Pandina GJ. Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents. J Child Adolesc Psychopharmacol. 2008;18:337\u201345.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"31_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.eurpsy.2015.11.004","volume":"32","author":"SZ Levine","year":"2016","unstructured":"Levine SZ, Kodesh A, Goldberg Y, Reichenberg A, Furukawa TA, Kolevzon A, et al. Initial severity and efficacy of risperidone in autism: Results from the RUPP trial. Eur Psychiatry. 2016;32:16\u201320.","journal-title":"Eur Psychiatry"},{"key":"31_CR5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s10803-006-0234-7","volume":"37","author":"GJ Pandina","year":"2007","unstructured":"Pandina GJ, Bossie CA, Youssef E, Zhu Y, Dunbar F. Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord. 2007;37:367\u201373.","journal-title":"J Autism Dev Disord"},{"key":"31_CR6","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.biopsych.2006.02.032","volume":"61","author":"GM Anderson","year":"2007","unstructured":"Anderson GM, Scahill L, McCracken JT, McDougle CJ, Aman MG, Tierney E, et al. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry. 2007;61:545\u201350.","journal-title":"Biol Psychiatry"},{"key":"31_CR7","first-page":"191","volume":"11","author":"Y Hongkaew","year":"2015","unstructured":"Hongkaew Y, Ngamsamut N, Puangpetch A, Vanwong N, Srisawasdi P, Chamnanphon M, et al. Hyperprolactinemia in Thai children and adolescents with autism spectrum disorder treated with risperidone. Neuropsychiatr Dis Treat. 2015;11:191\u20136.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"31_CR8","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/bcpt.12570","volume":"119","author":"N Ngamsamut","year":"2016","unstructured":"Ngamsamut N, Hongkaew Y, Vanwong N, Srisawasdi P, Puangpetch A, Chamkrachangpada B, et al. 9-Hydroxyrisperidone-induced hyperprolactinaemia in thai children and adolescents with autism spectrum disorder. Basic Clin Pharmacol Toxicol. 2016;119:267\u201372.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"31_CR9","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1159\/000337910","volume":"77","author":"Y Roke","year":"2012","unstructured":"Roke Y, van Harten PN, Buitelaar JK, Tenback DE, de Rijke YB, Boot AM. Antipsychotic-induced hyperprolactinemia and testosterone levels in boys. Horm Res Paediatr. 2012;77:235\u201340.","journal-title":"Horm Res Paediatr"},{"key":"31_CR10","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1089\/cap.2015.0094","volume":"25","author":"A Santos Junior dos","year":"2015","unstructured":"dos Santos Junior A, Henriques TB, de Mello MP, Ferreira Neto AP, Paes LA, Della Torre OH, et al. Hyperprolactinemia in children and adolescents with use of risperidone: clinical and molecular genetics aspects. J Child Adolesc Psychopharmacol. 2015;25:738\u201348.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"31_CR11","first-page":"418","volume":"10","author":"CT Correia","year":"2010","unstructured":"Correia CT, Almeida JP, Santos PE, Sequeira AF, Marques CE, Miguel TS, et al. Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. Pharm J. 2010;10:418\u201330.","journal-title":"Pharm J"},{"key":"31_CR12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s10928-012-9253-5","volume":"39","author":"HD Yoo","year":"2012","unstructured":"Yoo HD, Cho HY, Lee SN, Yoon H, Lee YB. Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1. J Pharmacokinet Pharmacodyn. 2012;39:329\u201341.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"31_CR13","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s40262-015-0289-8","volume":"54","author":"F Vandenberghe","year":"2015","unstructured":"Vandenberghe F, Guidi M, Choong E, von Gunten A, Conus P, Csajka C, et al. Genetics-based population pharmacokinetics and pharmacodynamics of risperidone in a psychiatric cohort. Clin Pharmacokinet. 2015;54:1259\u201372.","journal-title":"Clin Pharmacokinet"},{"key":"31_CR14","doi-asserted-by":"publisher","first-page":"465","DOI":"10.2165\/11531730-000000000-00000","volume":"49","author":"A Thyssen","year":"2010","unstructured":"Thyssen A, Vermeulen A, Fuseau E, Fabre MA, Mannaert E. Population pharmacokinetics of oral risperidone in children, adolescents and adults with psychiatric disorders. Clin Pharmacokinet. 2010;49:465\u201378.","journal-title":"Clin Pharmacokinet"},{"key":"31_CR15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1476-5381.2011.01385.x","volume":"164","author":"HD Yoo","year":"2011","unstructured":"Yoo HD, Lee SN, Kang HA, Cho HY, Lee IK, Lee YB. Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10\/*10. Br J Pharmacol. 2011;164:433\u201343.","journal-title":"Br J Pharmacol"},{"key":"31_CR16","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.gpb.2016.03.008","volume":"14","author":"S Ahmed","year":"2016","unstructured":"Ahmed S, Zhou Z, Zhou J, Chen SQ. Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine. Genomics Proteomics Bioinformatics. 2016;14:298\u2013313.","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"31_CR17","first-page":"131","volume":"9","author":"A Puangpetch","year":"2016","unstructured":"Puangpetch A, Vanwong N, Nuntamool N, Hongkaew Y, Chamnanphon M, Sukasem C. CYP2D6 polymorphisms and their influence on risperidone treatment. Pharmgenomics Pers Med. 2016;9:131\u201347.","journal-title":"Pharmgenomics Pers Med"},{"key":"31_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/JCP.0000000000000474","volume":"36","author":"C Sukasem","year":"2016","unstructured":"Sukasem C, Hongkaew Y, Ngamsamut N, Puangpetch A, Vanwong N, Chamnanphon M, et al. Impact of pharmacogenetic markers of CYP2D6 and DRD2 on prolactin response in risperidone-treated thai children and adolescents with autism spectrum disorders. J Clin Psychopharmacol. 2016;36:141\u20136.","journal-title":"J Clin Psychopharmacol"},{"key":"31_CR19","doi-asserted-by":"publisher","first-page":"542543","DOI":"10.1155\/2015\/542543","volume":"2015","author":"SM Wakil","year":"2015","unstructured":"Wakil SM, Nguyen C, Muiya NP, Andres E, Lykowska-Tarnowska A, Baz B, et al. The affymetrix DMET plus platform reveals unique distribution of ADME-related variants in ethnic Arabs. Dis Markers. 2015;2015:542543.","journal-title":"Dis Markers"},{"key":"31_CR20","doi-asserted-by":"publisher","first-page":"54028","DOI":"10.18632\/oncotarget.9927","volume":"7","author":"M Arbitrio","year":"2016","unstructured":"Arbitrio M, Di Martino MT, Scionti F, Agapito G, Guzzi PH, Cannataro M, et al. DMET (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine. Oncotarget. 2016;7:54028\u201350.","journal-title":"Oncotarget"},{"key":"31_CR21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2165\/00148581-200709050-00006","volume":"9","author":"LJ Scott","year":"2007","unstructured":"Scott LJ, Dhillon S. Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents. Paediatr Drugs. 2007;9:343\u201354.","journal-title":"Paediatr Drugs"},{"key":"31_CR22","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1515\/cclm.2002.202","volume":"40","author":"MW Elmlinger","year":"2002","unstructured":"Elmlinger MW, Kuhnel W, Ranke MB. Reference ranges for serum concentrations of lutropin (LH), follitropin (FSH), estradiol (E2), prolactin, progesterone, sex hormone-binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEAS), cortisol and ferritin in neonates, children and young adults. Clin Chem Lab Med. 2002;40:1151\u201360.","journal-title":"Clin Chem Lab Med"},{"key":"31_CR23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1067\/msy.2001.112635","volume":"130","author":"ME Fernandez Zapico","year":"2001","unstructured":"Fernandez Zapico ME, Ahmad US, Urrutia R. DNA microarrays: revolutionary insight into the living genome. Surgery. 2001;130:403\u20137.","journal-title":"Surgery"},{"key":"31_CR24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/978-1-60761-663-4_7","volume":"632","author":"JK Burmester","year":"2010","unstructured":"Burmester JK, Sedova M, Shapero MH, Mansfield E. DMET microarray technology for pharmacogenomics-based personalized medicine. Methods Mol Biol. 2010;632:99\u2013124.","journal-title":"Methods Mol Biol"},{"key":"31_CR25","doi-asserted-by":"publisher","first-page":"e33968","DOI":"10.1371\/journal.pone.0033968","volume":"7","author":"Y Hu","year":"2012","unstructured":"Hu Y, Ehli EA, Nelson K, Bohlen K, Lynch C, Huizenga P, et al. Genotyping performance between saliva and blood-derived genomic DNAs on the DMET array: a comparison. PloS One. 2012;7:e33968.","journal-title":"PloS One"},{"key":"31_CR26","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/bioinformatics\/bth457","volume":"21","author":"JC Barrett","year":"2005","unstructured":"Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263\u20135.","journal-title":"Bioinformatics"},{"key":"31_CR27","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/hdy.2016.121","volume":"118","author":"A Maurer","year":"2017","unstructured":"Maurer A, Sannemann W, Leon J, Pillen K. Estimating parent-specific QTL effects through cumulating linked identity-by-state SNP effects in multiparental populations. Heredity (Edinb). 2017;118:477\u201385.","journal-title":"Heredity (Edinb)"},{"key":"31_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/978-1-62703-435-7_5","volume":"1015","author":"T Hartshorne","year":"2013","unstructured":"Hartshorne T. TaqMan(R) drug metabolism genotyping assays for the detection of human polymorphisms involved in drug metabolism. Methods Mol Biol. 2013;1015:87\u201396.","journal-title":"Methods Mol Biol"},{"key":"31_CR29","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/clpt.2012.95","volume":"92","author":"CA Fernandez","year":"2012","unstructured":"Fernandez CA, Smith C, Yang W, Lorier R, Crews KR, Kornegay N, et al. Concordance of DMET plus genotyping results with those of orthogonal genotyping methods. Clin Pharmacol Ther. 2012;92:360\u20135.","journal-title":"Clin Pharmacol Ther"},{"key":"31_CR30","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/1479-7364-4-4-238","volume":"4","author":"SC Marques","year":"2010","unstructured":"Marques SC, Ikediobi ON. The clinical application of UGT1A1 pharmacogenetic testing: gene-environment interactions. Hum Genomics. 2010;4:238\u201349.","journal-title":"Hum Genomics"},{"key":"31_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1017\/S1461145703003249","volume":"6","author":"J Leon de","year":"2003","unstructured":"de Leon J. Glucuronidation enzymes, genes and psychiatry. Int J Neuropsychopharmacol. 2003;6:57\u201372.","journal-title":"Int J Neuropsychopharmacol"},{"key":"31_CR32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4172\/2161-1459.1000117","volume":"3","author":"C \u00c1lamo","year":"2013","unstructured":"\u00c1lamo C, L\u00f3pez-Mu\u00f1oz F. The pharmacological role and clinical applications of antipsychotics\u2019 active metabolites: paliperidone versus risperidone. Clin Exp Pharmacol. 2013;3:117.","journal-title":"Clin Exp Pharmacol"},{"key":"31_CR33","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/s11920-012-0284-9","volume":"14","author":"BA English","year":"2012","unstructured":"English BA, Dortch M, Ereshefsky L, Jhee S. Clinically significant psychotropic drug-drug interactions in the primary care setting. Curr Psychiatry Rep. 2012;14:376\u201390.","journal-title":"Curr Psychiatry Rep"},{"key":"31_CR34","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/978-3-319-27883-4_16","volume-title":"Applied clinical pharmacokinetics and pharmacodynamics of psychopharmacological agents","author":"ML Lu","year":"2016","unstructured":"Lu M-L, Lane H-Y. Clinically significant interactions with antipsychotics. In: Jann MW, Penzak SR, Cohen LJ, editors.. Applied clinical pharmacokinetics and pharmacodynamics of psychopharmacological agents. Cham: Springer International Publishing; 2016. p. 397\u2013421."},{"key":"31_CR35","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/15622975.2016.1224926","volume":"18","author":"SA Ivanova","year":"2017","unstructured":"Ivanova SA, Osmanova DZ, Freidin MB, Fedorenko OY, Boiko AS, Pozhidaev IV, et al. Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia. World J Biol Psychiatry. 2017;18:239\u201346.","journal-title":"World J Biol Psychiatry"},{"key":"31_CR36","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/FPC.0b013e328329a60f","volume":"19","author":"CA Calarge","year":"2009","unstructured":"Calarge CA, Ellingrod VL, Acion L, Miller DD, Moline J, Tansey MJ, et al. Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet. Genomics. 2009;19:373\u201382.","journal-title":"Pharmacogenet. Genomics"},{"key":"31_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/tpj.2012.45","volume":"13","author":"SC Sim","year":"2013","unstructured":"Sim SC, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics J. 2013;13:1\u201311.","journal-title":"Pharmacogenomics J"},{"key":"31_CR38","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1177\/1359786806066059","volume":"20","author":"GM Murphy Jr.","year":"2006","unstructured":"Murphy GM Jr.. Application of microarray technology in psychotropic drug trials. J Psychopharmacol. 2006;20:72\u20138.","journal-title":"J Psychopharmacol"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41397-018-0031-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41397-018-0031-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41397-018-0031-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T20:59:30Z","timestamp":1684616370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-018-0031-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,29]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["31"],"URL":"https:\/\/doi.org\/10.1038\/s41397-018-0031-7","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,29]]},"assertion":[{"value":"15 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}